Avalon GloboCare Corp. (ALBT)

US — Real Estate Sector
Peers: ACNDF  ASPZ  ADPPF  AZLCZ  ABCP  AANNF  BREUF  AGTK 

Automate Your Wheel Strategy on ALBT

With Tiblio's Option Bot, you can configure your own wheel strategy including ALBT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALBT
  • Rev/Share 0.6271
  • Book/Share -2.3952
  • PB -1.5448
  • Debt/Equity -0.0306
  • CurrentRatio 0.1934
  • ROIC 1.0645

 

  • MktCap 7007689.0
  • FreeCF/Share -3.6042
  • PFCF -1.1968
  • PE -0.6666
  • Debt/Assets 0.0112
  • DivYield 0
  • ROE -2.7684

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Shareholder Alert: The Ademi Firm investigates whether Avalon GloboCare Corp. is obtaining a Fair Price for its Public Shareholders
ALBT
Published: March 10, 2025 by: Business Wire
Sentiment: Neutral

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Avalon (Nasdaq: ALBT) for possible breaches of fiduciary duty and other violations of law in its transaction with YOOV. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Avalon stockholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV.

Read More
image for news Shareholder Alert: The Ademi Firm investigates whether Avalon GloboCare Corp. is obtaining a Fair Price for its Public Shareholders

About Avalon GloboCare Corp. (ALBT)

  • IPO Date 2018-03-27
  • Website https://www.avalon-globocare.com
  • Industry Real Estate - Services
  • CEO Dr. David K. Jin M.D., Ph.D.
  • Employees 4
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.